Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer
Acta Radiologica Open · 2020-07 · 9 (7)
DOI: 10.1177/2058460120938744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Radiologica Open, online erschienen am 06.07.2020. Verfasst von Yukinori Okada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast cancer has a poor prognosis due to the high risk of distant metastasis.
Purpose
To identify the prognosticators of brain metastasis from breast cancer treated by whole-brain radiotherapy. Material and Methods We evaluated patients diagnosed with primary brain metastasis without carcinomatous meningitis from breast cancer and had undergone whole-brain radiotherapy as initial treatment between 1 January 2010 and 30 September 2019. We investigated associations between overall survival time from diagnosis using cranial contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) and the following parameters: (i) age; (ii) sex; (iii) time to appearance of brain metastasis; (iv) other metastasis at appearance of brain metastasis; (v) blood test; (vi) symptoms at time of brain metastasis; (vii) whole-brain radiotherapy dose; (viii) whether whole-brain radiotherapy was completed; (ix) course of chemo- or radiotherapy; (x) subtype; (xi) additional irradiation after whole-brain radiotherapy; (xii) pathology; and (xiii) imaging findings.
Results
We evaluated 29 consecutive female patients (mean age 55.2 ± 12.1 years). Median overall survival time after diagnosis on cranial contrast-enhanced MRI/CT was 135 days (range 16–2112 days). Multivariate stepwise analysis of the three parameters of lactate dehydrogenase, dose, and subtype identified the following significant differences: Hazard Ratio (HR) for dose (discontinued, 30 Gy/10 fractions, 31.5 Gy/11 fractions, 32.5 Gy/11 fractions, 37.5 Gy/15 fractions) was 0.08 (95% confidence interval [CI] 0.02–0.30, P < 0.01), and HR for subtype (luminal, HER2, triple-negative) was 2.70 (95% CI 1.16–6.243, P < 0.01).
Conclusion
HER2-type and 37.5 Gy/15 fractions are good prognostic factor after whole-brain radiotherapy in breast cancer with brain metastases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
- Department of Surgery, Division of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.
ORCID-Profile: Yukinori Okada
Zitieren
APA
Okada, Y., Kobayashi, M., Shinozaki, M., Abe, T., Kanemaki, Y., Nakamura, N., & Kojima, Y. (2020). Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer. Acta Radiologica Open, 9(7). https://doi.org/10.1177/2058460120938744
Vancouver
Okada Y, Kobayashi M, Shinozaki M, Abe T, Kanemaki Y, Nakamura N, et al. Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer. Acta Radiologica Open. 2020;9(7). doi:10.1177/2058460120938744
BibTeX
@article{Okada2020,
author = {Okada, Yukinori and Kobayashi, Mariko and Shinozaki, Mio and Abe, Tatsuyuki and Kanemaki, Yoshihide and Nakamura, Naoki and Kojima, Yasuyuki},
title = {Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer},
journal = {Acta Radiologica Open},
year = {2020},
volume = {9},
number = {7},
doi = {10.1177/2058460120938744}
}
EUVIMED